On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00. The firm ...

On Thursday, Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently trading at $141.24, with a steady price target of $192.00.

Neurocrine Bioscience Inc. said in a federal lawsuit that Spruce Biosciences Inc. is threatening patent litigation over its new rare disease drug Crenessity due to a “desperate need for cash”.

Johanna Mercier, Chief Commercial Officer at Gilead Sciences, Inc. (NASDAQ:GILD), sold 5,490 shares of company stock at a price of $73.98 per share,... ByInvesting.com • Aug 14, 2024 FDA grants ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $121.00. Discover outperforming stocks and invest smarter ...

An End of Phase 2 meeting for NBI-1117568 (NBI-’568, an oral, muscarinic M4 selective agonist) has been completed with the US Food & Drug Administration and Neurocrine reiterated its intentions ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) ...

Ashley Allan is making history in her role as executive director for CAH brand marketing at Neurocrine Biosciences, overseeing a cross-functional team that launched the first treatment for CAH (a ...